Does monitoring drug plasma levels of dabigatran improve safety?
An investigation suggests that recommendations for dabigatran may be flawed because the manufacturer withheld evidence that monitoring plasma levels could improve safety.
In an investigation by The BMJ Deborah Cohen finds that recommendations for use of new generation oral anticoagulants may be flawed because regulators did not see evidence showing that monitoring drug plasma levels could improve safety
David D. Cohen (2014) studied this question.